The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials

Phytotherapy Research

Volumn 30, Issue 2, 2016, Pages 175-183

  Al Karawi, Dalia ^a   Al Mamoori, Doaa Alem ^b   Tayyar, Yaman ^c  

^a BASRA UNIVERSITY   (Iraq)

^b BAGHDAD TEACHING HOSPITAL   (Iraq)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

curcumin; major depressive disorders

Indexed keywords

ANTIDEPRESSANT AGENT; BCM 95; CURCUMIN; PIPERINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; CARDIOVASCULAR RISK; DIZZINESS; DRUG EFFICACY; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; META ANALYSIS; NAUSEA; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TACHYCARDIA; TREATMENT DURATION; CHEMISTRY; CURCUMA; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; QUALITY OF LIFE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CURCUMA; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84956896027     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5524     Document Type: Review

References (63)

1. Aggarwal BB, Harikumar KB,. 2009. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The international Journal Of Biochemistry & Cell Biology 41 (1): 40-59.
2. Aggarwal BB, Gupta SC, Sung B,. 2013. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169 (8): 1672-1692.
3. Ahmed T, Gilani AH,. 2014. Therapeutic potential of turmeric in Alzheimer's disease: curcumin or curcuminoids? Phytother Res 28 (4): 517-525.
4. Andrade C,. 2014. A critical examination of studies on curcumin for depression. J Clin Psychiatry 75 (10): e1110-2.
5. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S,. 2008. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax™), a novel bioenhanced preparation of curcumin. Indian J Pharmaceut Sci 70 (4): 445-449.
6. Bergman J, Miodownik C, Bersudsky Y, et al., 2013. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol 36 (3): 73-77.
7. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BW,. 2015. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 51: 164-175.
8. Chandra V, Pandav R, Dodge HH, et al., 2001. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 57 (6): 985-989.
9. Cheng AL, Hsu CH, Lin JK, et al., 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (4b): 2895-2900.
10. Davidson JR,. 2010. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 71 (Suppl E1): e04.
11. DerSimonian R, Laird N,. 1986. Meta-analysis in clinical trials. Control Clin Trials 7 (3): 177-188.
12. Du P, Tang HY, Li X, et al., 2012. Anticonvulsive and antioxidant effects of curcumin on pilocarpine-induced seizures in rats. Chin Med J (Engl) 125 (11): 1975-1979.
13. Esmaily H, Sahebkar A, Iranshahi M, et al., 2015. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 21 (5): 332-338.
14. Fiske A, Wetherell JL, Gatz M,. 2009. Depression in older adults. Annu Rev Clin Psychol 5: 363-389.
15. van Geffen ECG, van der Wal SW, van Hulten R, de Groot MCH, Egberts ACG, Heerdink ER,. 2007. Evaluation of patients' experiences with antidepressants reported by means of a medicine reporting system. Eur J Clin Pharmacol 63 (12): 1193-1199.
16. Hawley CJ, Gale TM, Smith PS, et al., 2013. Equations for converting scores between depression scales (MADRS, SRS, PHQ-9 and BDI-II): good statistical, but weak idiographic, validity. Hum Psychopharmacol 28 (6): 544-551.
17. Hayley S, Poulter MO, Merali Z, Anisman H,. 2005. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 135 (3): 659-678.
18. Higgins JPT,. 2008. Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 37 (5): 1158-1160.
19. Higgins JPT, Green S, (editors). 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, Available from www.cochrane-handbook.org.
20. Huang EJ, Reichardt LF,. 2001. Neurohins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736.
21. Judd LL,. 1997. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 54 (11): 989-991.
22. Jurenka JS,. 2009. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14 (2): 141-153.
23. Kapur S, Mann JJ,. 1992. Role of the dopaminergic system in depression. Biol Psychiatry 32 (1): 1-17.
24. Kaymaz N, van Os J, Loonen AJ, Nolen WA,. 2008. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 69 (9): 1423-1436.
25. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE,. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62 (6): 617-627.
26. Khairova RA, Machado-Vieira R, Du J, Manji HK,. 2009. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 12 (4): 561-578.
27. Kruijshaar ME, Barendregt J, Vos T, de Graaf R, Spijker J, Andrews G,. 2005. Lifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall bias. Eur J Epidemiol 20 (1): 103-111.
28. Kulkarni SK, Dhir A,. 2010. An overview of curcumin in neurological disorders. Indian J Pharmaceut Sci 72 (2): 149-154.
29. Kulkarni SK, Bhutani MK, Bishnoi M,. 2008. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 201 (3): 435-442.
30. Lopresti AL, Hood SD, Drummond PD,. 2012. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 26 (12): 1512-1524.
31. Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD,. 2014. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord 167: 368-375.
32. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I,. 1991. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146 (9): 3032-3037.
33. Meng B, Li J, Cao H,. 2013. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des 19 (11): 2101-2113.
34. Menon VP, Sudheer AR,. 2007. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105-125.
35. Michel TM, Pulschen D, Thome J,. 2012. The role of oxidative stress in depressive disorders. Curr Pharm Des 18 (36): 5890-5899.
36. Moher D, Liberati A, Tetzlaff J, Altman DG,. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (4): 264-269, w64.
37. Monteiro R, Azevedo I,. 2010. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010: 289645.
38. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH,. 2006. Curry consumption and cognitive function in the elderly. Am J Epidemiol 164 (9): 898-906.
39. Owens MJ, Nemeroff CB,. 1994. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (2): 288-295.
40. Palta P, Samuel LJ, Miller ER 3rd, Szanton SL,. 2014. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med 76 (1): 12-19.
41. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A,. 2014. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 28 (10): 1461-1467.
42. Panahi Y, Badeli R, Karami GR, Sahebkar A,. 2015. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29 (1): 17-21.
43. Quality Assessment Tool for Quantitative Studies. 2008 [online], available: http://www.nccmt.ca/registry/view/eng/14.html.
44. Qualls Z, Brown D, Ramlochansingh C, Hurley LL, Tizabi Y,. 2014. Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease. Neurotox Res 25 (1): 81-89.
45. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R,. 1995. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94 (1): 79-83.
46. Rush AJ, Trivedi MH, Ibrahim HM, et al., 2003. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54 (5): 573-583.
47. Sahebkar A,. 2014. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 28 (5): 633-642.
48. Sahebkar A, Mohammadi A, Atabati A, et al., 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27 (12): 1883-1888.
49. Sahebkar A, Serban M-C, Ursoniu S, Banach M,. 2015. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods 18, 898-909. doi: 10.1016/j.jff.2015.01.005
50. Sandur SK, et al., 2007. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med 43 (4): 568-580.
51. Sanmukhani J, Satodia V, Trivedi J, et al., 2014. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 28 (4): 579-585.
52. Sansone RA, Sansone LA,. 2012. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci 9 (5-6): 41-46.
53. Sivertsen H, Bjorklof GH, Engedal K, Selbaek G, Helvik AS,. 2015. Depression and quality of life in older persons: a review. Dement Geriatr Cogn Disord 40 (5-6): 311-339.
54. Tizabi Y, Hurley LL, Qualls Z, Akinfiresoye L,. 2014. Relevance of the anti-inflammatory properties of curcumin in neurodegenerative diseases and depression. Molecules 19 (12): 20864-20879.
55. Toda S, Miyase T, Arichi H, Tanizawa H, Takino Y,. 1985. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull (Tokyo) 33 (4): 1725-1728.
56. Unützer J, Park M,. 2012. Older adults with severe, treatment-resistant depression: 'I got my mother back'. JAMA 308 (9): 909-918.
57. Vadhan-Raj S, Weber D, Wang M, et al., 2007. Curcumin downregulates NF-Cyrillic capital letter kaB and related genes in patients with multiple myeloma: results of a phase 1/2 study. Blood 110 (11): 357a.
58. Vas CJ, et al., 2001. Prevalence of dementia in an urban Indian population. Int Psychogeriatr 13 (4): 439-450.
59. Vittengl JR, Clark LA, Kraft D, Jarrett RB,. 2005. Multiple measures, methods, and moments: a factor-analytic investigation of change in depressive symptoms during acute-phase cognitive therapy for depression. Psychol Med 35 (5): 693-704.
60. Wahlstrom B, Blennow G,. 1978. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43 (2): 86-92.
61. Xu Y, Ku BS, Yao HY, et al., 2005. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82 (1): 200-206.
62. Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL,. 2015. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 35 (4): 406-410.
63. Zhang L, Luo J, Zhang M, Yao W, Ma X, Yu SY,. 2014. Effects of curcumin on chronic, unpredictable, mild, stress-induced depressive-like behaviour and structural plasticity in the lateral amygdala of rats. Int J Neuropsychopharmacol 17 (5): 793-806.